Imidazoles Patents (Class 514/396)
-
Patent number: 8513294Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumor tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: GrantFiled: January 13, 2011Date of Patent: August 20, 2013Assignees: Osta Biotechnologies, Queens University at Kingston, The Sir Mortimer B. Davis-Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Patent number: 8507542Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: GrantFiled: December 24, 2012Date of Patent: August 13, 2013Assignee: Hospira, Inc.Inventors: Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis Stalker, Edward Koo
-
Publication number: 20130202657Abstract: The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02.Type: ApplicationFiled: May 20, 2011Publication date: August 8, 2013Applicants: BASF SE, President and Fellows of Harvard CollegeInventors: Kosta Ladavac, Rodrigo E. Guerra, David Kaz, Vinothan Manoharan, Jens B. Rieger, Roland S. Koltzenburg, David A. Weitz
-
Patent number: 8501743Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole.Type: GrantFiled: November 4, 2008Date of Patent: August 6, 2013Assignee: Conopco, Inc.Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel, Colina MacKay
-
Patent number: 8501798Abstract: The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: June 19, 2012Date of Patent: August 6, 2013Assignee: Theravance, Inc.Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Robert Murray McKinnell
-
Patent number: 8501796Abstract: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: GrantFiled: September 15, 2011Date of Patent: August 6, 2013Assignee: Allergan, Inc.Inventors: Mohammad I. Dibas, Daniel W. Gil, John E. Donello, Ken Chow, Liming Wang, Michael E. Garst
-
Patent number: 8492553Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: September 7, 2012Date of Patent: July 23, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Patent number: 8492568Abstract: The present invention provides chromane derivatives as transient receptor potential vanilloid (TRPV) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.Type: GrantFiled: May 19, 2009Date of Patent: July 23, 2013Assignee: Glenmark Pharamceuticals S.A.Inventors: V. S. Prasada Rao Lingam, Abraham Thomas, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 8486985Abstract: The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders.Type: GrantFiled: May 11, 2009Date of Patent: July 16, 2013Assignee: Allergan, Inc.Inventors: Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh
-
Patent number: 8486980Abstract: Provided is a tricyclic compound having a PPAR ? agonist activity, which is represented by the general formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A represents aryl or the like, B and C are the same or different and each represents an aromatic carbocycle or the like, R4-R9 are the same or different and each represents hydrogen or the like, V represents a single bond or the like, R10 and R11 are the same or different and each represents hydrogen or the like, or a pharmaceutically acceptable salt thereof or the like:Type: GrantFiled: August 6, 2009Date of Patent: July 16, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Arata Yanagisawa, Keiji Uehara, Masahiro Matsubara, Kimihisa Ueno, Michihiko Suzuki, Takeshi Kuboyama, Keisuke Yamamoto, Tomohiro Tamura
-
Publication number: 20130178465Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.Type: ApplicationFiled: December 11, 2012Publication date: July 11, 2013Applicant: RECRO PHARMA, INC.Inventor: Recro Pharma, Inc.
-
Publication number: 20130172357Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: February 5, 2013Publication date: July 4, 2013Applicant: EYE THERAPIES LLCInventor: Eye Therapies LLC
-
Publication number: 20130165488Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.Type: ApplicationFiled: February 28, 2013Publication date: June 27, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: The Trustees of the University of Pennsylvania
-
Patent number: 8470862Abstract: A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof.Type: GrantFiled: April 28, 2011Date of Patent: June 25, 2013Assignee: Recro Pharma, Inc.Inventors: Riitta Heino, Tiina Leino, Tarja Lehtimäki
-
Patent number: 8461192Abstract: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?,2?,3?,4?)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.Type: GrantFiled: September 15, 2008Date of Patent: June 11, 2013Assignees: The University of South Florida, The United States of America Department of Veterans Affairs, The University of Florida Research Foundation, Inc.Inventors: Mildred Acevedo-Duncan, Shraddha R. Desai, Hla Yee Win, David A. Ostrov, Prajit P. Pillai, Diondra D. Hill
-
Publication number: 20130143938Abstract: Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists.Type: ApplicationFiled: February 1, 2013Publication date: June 6, 2013Applicant: Eye Therapies LLCInventor: Eye Therapies LLC
-
Patent number: 8455527Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: November 15, 2012Date of Patent: June 4, 2013Assignee: Hospira, Inc.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Publication number: 20130136784Abstract: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Inventor: Robert J. Staab
-
Patent number: 8450318Abstract: Molecules having a spacer unit, linker and recognition unit(s) are used for the treatment of various diseases, disorders and conditions. The compounds are useful in treating infectious diseases and diseases, disorders or conditions related thereto. Further, the methods for treating diseases, disorders or conditions involve recognition and binding of carbohydrate structures.Type: GrantFiled: March 18, 2008Date of Patent: May 28, 2013Assignees: K.U. Leuven Research and DevelopmentInventors: Monika Mazik, Jan Balzarini
-
Patent number: 8450353Abstract: Topical compositions and methods of use to treat symptoms of reduced skin elasticity are provided comprising desthiobiotin and certain desthiobiotin analogues. These compounds are effective in stimulating LOXL-1 activity and can thus increase elastin remodeling and improve appearance of fine lines, wrinkles, skin sagging and other symptoms of reduced elastin function.Type: GrantFiled: November 19, 2008Date of Patent: May 28, 2013Assignee: Avon Products, Inc.Inventors: Dmitri S. Ptchelintsev, Xiaochun Luo, Siming W. Chen
-
Patent number: 8450354Abstract: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.Type: GrantFiled: March 21, 2011Date of Patent: May 28, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Mohan Rao, Raju Bore Gowda, Robert Carl Andrews, Rongyuan Xie, Soumya P. Sahoo, Tan Ren, William Kenneth Banner
-
Publication number: 20130131133Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.Type: ApplicationFiled: November 19, 2012Publication date: May 23, 2013Applicant: Allergan, Inc.Inventor: Allergan, Inc.
-
Patent number: 8445526Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: GrantFiled: August 14, 2012Date of Patent: May 21, 2013Assignee: Glaucoma & Nasal Therapies LLCInventor: Gerald Horn
-
Patent number: 8445525Abstract: The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.Type: GrantFiled: December 2, 2010Date of Patent: May 21, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Henning Priepke, Kai Gerlach, Roland Pfau, Norbert Hauel, Iris Kauffmann-Hefner, Georg Dahmann, Herbert Nar, Sandra Handschuh, Wolfgang Wienen, Annette Schuler-Metz
-
Patent number: 8436002Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.Type: GrantFiled: October 20, 2010Date of Patent: May 7, 2013Assignee: Eli Lilly and CompanyInventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, Jr., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
-
Patent number: 8435996Abstract: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: GrantFiled: July 31, 2008Date of Patent: May 7, 2013Assignee: Synta Pharmaceuticals Corp.Inventor: Shoujun Chen
-
Patent number: 8436033Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: November 15, 2012Date of Patent: May 7, 2013Assignee: Hospira, Inc.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Patent number: 8436036Abstract: Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.Type: GrantFiled: April 23, 2010Date of Patent: May 7, 2013Assignee: Janssen R&D IrelandInventors: Samuel Dominique Demin, David McGowan, Stefaan Julien Last, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20130096172Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: ApplicationFiled: December 24, 2012Publication date: April 18, 2013Applicant: HOSPIRA, INC.Inventor: HOSPIRA, INC.
-
Publication number: 20130096171Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: ApplicationFiled: December 24, 2012Publication date: April 18, 2013Applicant: HOSPIRA, INC.Inventor: HOSPIRA, INC.
-
Publication number: 20130096170Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: ApplicationFiled: January 4, 2012Publication date: April 18, 2013Applicant: HOSPIRA, INC.Inventors: Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis James Stalker, Edward Koo
-
Patent number: 8414931Abstract: Disclosed is a wood preservative composition comprising micronized copper and copper-amine complex, wherein the copper component of the copper amine complex is from about 5% to about 50% by weight, based upon the total weight of copper in the composition. The copper amine complex serves to avoid wood surface “chalking” that is otherwise attributable to the presence of micronized copper in copper-based slurries used to treat wood products. In addition, the copper-amine complex enhances the antimicrobial efficacy of the composition when used in wood treatment applications by facilitating cell wall penetration of the treated wood.Type: GrantFiled: September 13, 2012Date of Patent: April 9, 2013Assignee: Arch Wood Protection, Inc.Inventor: Jayesh P. Patel
-
Patent number: 8410155Abstract: The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R8a, R11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: GrantFiled: December 13, 2007Date of Patent: April 2, 2013Assignee: Bristol-Myers Squibb CompanyInventor: Donald J. P. Pinto
-
Patent number: 8410150Abstract: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 6, 2008Date of Patent: April 2, 2013Assignee: University Health NetworkInventors: Heinz W. Pauls, Peter Brent Sampson, Bryan T. Forrest, Radoslaw Laufer, Yong Liu, Miklos Feher, Yi Yao, Guohua Pan
-
Patent number: 8409550Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of at combination of retinoid boosters.Type: GrantFiled: June 21, 2012Date of Patent: April 2, 2013Assignee: Unilever Home & Personal Care, USA, Division of Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20130079344Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: ApplicationFiled: March 14, 2012Publication date: March 28, 2013Applicant: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Patent number: 8404728Abstract: This disclosure relates to materials and methods for inhibiting Botulinum neurotoxin, and more particularly to materials and methods for inhibiting the zinc endopeptidase of Botulinum neurotoxin serotypes A, D and/or E (BoNTA, BoNTD and/or BoNTE).Type: GrantFiled: July 29, 2010Date of Patent: March 26, 2013Assignees: Mayo Foundation for Medical Education and Research, U.S. Army Medical Research and Material CommandInventors: Yuan-Ping Pang, Jewn Giew Park, Shaohua Wang, Anuradha Vummenthala, Rajesh K Mishra, Jon Davis, Charles B. Millard, James J. Schmidt
-
Patent number: 8404732Abstract: Methods of treating and managing ulcerative colitis, using imidazole-based compounds that inhibit S1P lyase, are disclosed.Type: GrantFiled: January 4, 2012Date of Patent: March 26, 2013Assignee: Lexicon Pharmaceuticals, Inc.Inventors: David J. Augeri, Jeffrey Bagdanoff, Lakmal W. Boteju, Kenneth G. Carson, Theodore C. Jessop, Spencer David Kimball
-
Publication number: 20130072532Abstract: Analgesic topical formulations of dexmedetomidine and methods of use thereof in the treatment and management of pain and other conditions.Type: ApplicationFiled: January 7, 2011Publication date: March 21, 2013Applicant: Recro Pharma, Inc.Inventors: Geraldine A. Henwood, Randall J. Mack, Christopher T. Sharr, John J. Koleng, JR.
-
Patent number: 8399463Abstract: The invention relates to imidazole derivatives which have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The invention also relates to a pharmaceutically-suitable acid-addition salt of the above compound. The invention further relates to a composition comprising an imidazole derivative as described above, or a pharmaceutically-suitable acid-addition salt thereof, and to processes for preparing such compounds.Type: GrantFiled: September 19, 2011Date of Patent: March 19, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Patent number: 8389570Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: GrantFiled: August 12, 2011Date of Patent: March 5, 2013Assignee: Pharmacyclics, Inc.Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
-
Publication number: 20130052248Abstract: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal infection when released from the microcapsules (30).Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Inventors: Marcus Chun Wah YUEN, Joanne Yiu Wan YIP, Kevin CHEUK, Chi Wai KAN, Shuk Yan CHENG
-
Publication number: 20130045264Abstract: There is provided an antifouling coating composition capable of forming an antifouling coating film which has stable coating film consumption degree on ships, underwater structures and the like and which exhibits excellent antifouling property over a long term. The antifouling coating composition includes a hydrolyzable copolymer (A) and an antifouling agent (B), wherein the hydrolyzable copolymer (A) is, e.g., a metal salt bond-containing copolymer having a component unit derived from a monomer (a21) represented by the general formula (II): CH2?C(R2)—COO-M-O—CO—C(R2)?CH2??(II) [In the formula (II), M is zinc or copper, and R2 is a hydrogen atom or a methyl group], and a component unit derived from other unsaturated monomer (a22) copolymerizable with the monomer (a21), and wherein the antifouling agent (B) includes at least medetomidine.Type: ApplicationFiled: March 18, 2011Publication date: February 21, 2013Applicant: CHUGOKU MARINE PAINTS, LTD.Inventors: Satoshi Masuda, Yusuke Hayashi, Yukio Kozono
-
Patent number: 8372871Abstract: Compounds of general formula (I) below: are characterized in that A represents in particular a C5-C10 heterocyclic group, Y represents in particular a single bond, and B represents in particular an aryl or heteroaryl group.Type: GrantFiled: November 10, 2009Date of Patent: February 12, 2013Assignee: Centre National de la Recherche ScientifiqueInventors: Jean-Yves Winum, Jean-Louis Montero, Stephan Köhler
-
Publication number: 20130023490Abstract: The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Inventors: Albert BOECKH, Luiz Gustavo CRAMER, Mark D. SOLL
-
Patent number: 8357714Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.Type: GrantFiled: October 11, 2011Date of Patent: January 22, 2013Assignee: Voom, LLCInventor: Mark Silverberg
-
Patent number: 8357715Abstract: Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever.Type: GrantFiled: March 31, 2010Date of Patent: January 22, 2013Assignee: Janssen Pharmaceutica, NVInventors: John R. Carson, James J. McNally
-
Publication number: 20130012555Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment.Type: ApplicationFiled: January 12, 2012Publication date: January 10, 2013Inventors: Thomas Lake, Alan D. Snow
-
Patent number: 8344011Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.Type: GrantFiled: July 19, 2010Date of Patent: January 1, 2013Assignee: Janssen Pharmaceutica, N.V.Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
-
Patent number: 8344012Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: GrantFiled: September 4, 2009Date of Patent: January 1, 2013Assignee: Ardea Biosciences, Inc.Inventors: Esmir Gunic, Jean-Luc Girardet, David A. Paisner